Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC is a research paper published in Journal of Thoracic Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 98 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P30 CA016672
Jazz Pharmaceuticals
Grant: unidentified
unidentified
Bristol-Myers Squibb
Merck
Spectrum Pharmaceuticals
AstraZeneca
National Cancer Institute
GlaxoSmithKline
Johnson and Johnson
National Institutes of Health
F. Hoffmann-La Roche
Genentech
Jazz Pharmaceuticals
Sierra Oncology
AbbVie
Novartis
Boehringer Ingelheim
Eli Lilly and Company
Jounce Therapeutics
FWCI
4.19
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals